New pill tested to tame deadly Virus-Linked inflammation
NCT ID NCT06052618
Summary
This study is testing an oral drug called pacritinib for two rare, severe inflammatory diseases caused by the Kaposi sarcoma herpesvirus (KSHV) in people living with HIV. Up to 75 adults with either KSHV-associated multicentric Castleman disease (MCD) or KSHV inflammatory cytokine syndrome (KICS) will take the pill twice daily for up to 24 weeks. The main goal is to see if the drug can control the dangerous inflammation and provide clinical benefit.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KSHV INFLAMMATORY CYTOKINE SYNDROME (KICS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.